Drug incentive plan plus B2B business will induce illegal rebate

The government plan to introduce the controversial incentive plan for prescription of low-priced drugs, including B2B business, is triggering a backlash from the pharmaceutical industry and drug wholesalers.

The government said the plan will not only be helpful to the budget for national health insurance, but it will also lessen patients' financial burden.

However, critics say the plan wi...